Latest News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
02/27/17AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
REDWOOD CITY, Calif., Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 mcg) for the treatment of patients with m... 
Printer Friendly Version
02/23/17AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017
REDWOOD CITY, Calif., Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth quarter and yearly financial results after market close on Thursday, March 2nd, 2017. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ... 
Printer Friendly Version
02/16/17AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
- Howie Rosen to Continue on Board of Directors - REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Vincent J. Angotti has been appointed chief executive officer and a member of the company's board of directors, effective Monday, March 6, 2017. Mr. Angotti brings over two de... 
Printer Friendly Version
02/13/17AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., Feb. 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming podium presentation of comprehensive results from the DSUVIA™ SAP302 study of patients who presented to emergency departments with moderate-to-severe acute pain resulting from trauma or injury, including burns. The presen... 
Printer Friendly Version
02/07/17AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 7, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E. Morris, Chief Financial Officer, Head of Business Development will be presenting at the BIO CEO & Investor Conference, 2017 Disruptive Growth & Healthcare Conference, Small Cap Nation Family Off... 
Printer Friendly Version
01/08/17AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
· Expected FDA Acceptance of the NDA · Planned Submission of MAA in the EU · Potential Approval and Commercialization in the U.S. REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, provided guidance today on 2017 milestones for its lead product, ARX-04, known as DSUVIA™ (sufentanil sublingual tablet, 30 ... 
Printer Friendly Version
01/08/17AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the brand name, DSUVIA™ (sufentanil sublingual tablet, 30 mcg), for the company's investigational product candidate, ARX-04. In addition, AcelRx has applied t... 
Printer Friendly Version